Obesity Clinical Trials in Richmond, Virginia

9 studies are recruiting for obesity in Richmond, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   National Clinical Research /ID# 282007, Richmond, Virginia

   Locations

   45 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

   The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Clinical Research Partners, LLC, Richmond, Virginia

   Locations

   42 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07215559 on ClinicalTrials.gov

3. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

   The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   National Clin Res Inc., Richmond, Virginia

   Locations

   74 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07533175 on ClinicalTrials.gov

4. A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

   The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Whic…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   National Clin Res Inc., Richmond, Virginia

   Locations

   36 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07745504 on ClinicalTrials.gov

5. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

   The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kailera Clinical Site, Richmond, Virginia

   Locations

   59 in total

   Run by

   Kailera

   See if you can join NCT07284979 on ClinicalTrials.gov

6. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

   This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   National Clin Res Inc., Richmond, Virginia

   Locations

   303 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07564414 on ClinicalTrials.gov

7. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   VCU Health - Center for Endocrinology Diabetes and Metabolism, Richmond, Virginia

   Locations

   117 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

8. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Virginia Commonwealth University, Richmond, Virginia

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

9. Redefining BMI: The Body, Mind, and Inflammation Trial

   Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in re…

   Stage

   Not phased

   Ages

   18 to 25

   Site

   Virginia Commonwealth Universtity, Richmond, Virginia

   Run by

   Virginia Commonwealth University

   See if you can join NCT06532747 on ClinicalTrials.gov